Biophan to Receive Nano 50 ``Best of the Best'' Award for Innovation in Nanotechnology at NASA Tech Briefs Conference; CEO to Present Biophan's Nanotechnology Development Initiatives at Nano 2005 Forum in Boston
The official ceremony will take place at an awards dinner during the NASA Tech Briefs Nano 2005 conference November 10-11, to be held at the Marriot Boston Newton in Newton, MA. Biophan is being recognized for an innovative nanomaterial-based biothermal power source. Being developed by Biophan subsidiary TE-Bio, the biothermal power source converts body heat into electricity to power implantable medical devices.
“Biophan's research includes cutting-edge development in biomedical applications of nanotechnology”
"Biophan's research includes cutting-edge development in biomedical applications of nanotechnology," said Mr. Weiner. "The Nano 50 "Best of the Best" award recognizes one of our important development programs. We believe the Company will continue to demonstrate leadership in other market segments, such as MRI imaging and drug-delivery systems, through our nanotechnology-based solutions."
Biophan's TE-Bio subsidiary has an agreement with NASA for characterization and joint development of high-density, thermoelectric nanomaterials for use with implantable medical devices. Research is being jointly conducted by Biophan and NASA personnel at the NASA Ames Research Center for Nanotechnology in Moffett Field, CA.
Mr. Weiner will also make a special presentation of the Company's portfolio of nanotechnology-based biomedical applications on November 10th at 2:00 p.m., in Ballroom A-D. Biophan's nanotechnology solutions span a range of existing and emerging multi-billion-dollar markets in addition to the biothermal power source, such as drug-delivery and MRI safety and image compatibility of medical devices.
The nominations for the Nano 50 were judged by a panel of nanotechnology and MEMS experts. The technologies, products, and innovators receiving the 50 highest scores were named winners of the Nano 50 "Best of the Best" awards. Presented by Nanotech Briefs magazine, a digital publication from the publishers of NASA Tech Briefs, the Nano 50 recognizes the top 50 technologies, products, and innovators that have significantly impacted, or are expected to impact, the state of the art in nanotechnology.
About Nanotech Briefs
Nanotech Briefs, launched in January 2004, is a digital (PDF format) magazine from the publishers of NASA Tech Briefs - the country's largest-circulation design engineering magazine - that provides the best of government, industry and university nanotech innovations with real-world applications in areas such as electronics, materials, sensors, manufacturing, biomedical, optics/photonics, and aerospace/defense. Nanotech Briefs is the first small-tech publication specifically for design engineers who are designing tomorrow's nanotech products today. For more information, please visit www.nanotechbriefs.com. For more information on the NASA tech briefs Nano 2005 Boston conference, please visit http://www.techbriefs.com/nano/agenda.html
About Biophan Technologies
Biophan develops and markets a broad spectrum of next-generation technologies and products with commercial applications in a variety of multibillion-dollar healthcare market segments. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, and applications. This extensive intellectual property portfolio includes nanotechnology-based and other approaches to create enhancements for several medical products. Biophan's technology portfolio includes solutions developed to enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and effectively imaged by Magnetic Resonance Imaging (MRI) systems. Biophan is developing these same technologies to enable new MRI contrast agents. Other applications include drug delivery and power systems which derive energy from body heat. Biophan's intellectual property portfolio now includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology, medical device designs, radio frequency filters, thermoelectric materials and optical catheter technologies. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and effectively working with MRI, and to deliver other technologies which will improve the delivery of healthcare. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.